Hematological Malignancies
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Only parallel-group RCTs will be included, and only English-language literature will be included. Include short reports and conference abstracts. Non-inferiority trials are acceptable alongside superiority trials. RCTs of any phase may be included. Exclude trials that do not report safety data. The main inclusion criteria are as follows. (1) Trials in adult patients with hematological malignancies. (2) RCTs including CAR-T therapy. (3) Trials with adverse event results (cytokine release syndrome, neurotoxicity, infection, hypogammaglobulinemia, infusion reaction, cytopenia, macrophage activation syndrome/hemophagocytic lymphohistiocytosis, coagulopathy, tumor lysis syndrome).
Exclusion criteria
Exclusion criteria: (1) Systematic review or meta-analysis articles. (2) Non-RCT. (3) The republished research literature is excluded unless the research includes new findings related to adverse events listed in inclusion criteria. (4) Trials with no or insufficient safety outcomes at the time of the literature search.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the frequency of occurrence of cytokine release syndrome and neurotoxicity during the observation period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are the frequency of infections, hypogammaglobulinemia, infusion reactions, cytopenia, macrophage activation syndrome/hemophagocytic syndrome, coagulopathy, and tumor lysis syndrome over the observation period. | — |
Countries
Japan
Contacts
Public ContactKaoru Minegishi
Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation
Outcome results
None listed